Since ETP-ALL commonly presents mutations of genes involved in epigenetic regulation and BCL2 overexpression, the combination of azacytidine or decitabine with venetoclax is a reasonable option as a novel combination strategy. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.